Maureen is a co-founder and CEO of Hexagon Bio. Previously she was the director of the Genomes to Natural Products program at the Stanford Technology Genome Center, where she led technology development for discovery of drug-like metabolites using bioinformatics and synthetic biology. Maureen’s interdisciplinary background spans biology, genomics, and computer science, representing the interdisciplinary nature of Hexagon as a company.

Maureen has a Ph.D. in Biomedical Informatics from Stanford University, and a B.A. in Biology from the University of Notre Dame.

Tara is Chief Scientific Officer at Hexagon Bio. She previously served as Hexagon’s Senior Vice President, Research. Prior to joining Hexagon, Tara was an Executive Director of Oncology Research at Amgen where she led small molecule and large molecule programs in Oncology, Immuno-Oncology, Inflammation and Hematology. Notable accomplishments include initiation of Amgen’s KRAS G12C-targeting effort which resulted in the first approved KRAS targeting molecule, LUMAKRAS™ (sotorasib), and leadership of Amgen’s bispecific T cell engager platform, which resulted in several current clinical candidates.

Tara received her Ph.D. in Biochemistry from the California Institute of Technology and was a Damon Runyon Postdoctoral Fellow at the University of California, San Diego.

Bill is the former Senior Vice President and Therapeutic Area Head of Oncology Clinical Development at Gilead Sciences Inc. overseeing the company’s Oncology portfolio and collaboration programs. Prior to that, he held Chief Medical Officer roles at Arcus Biosciences and Bellicum Pharmaceuticals. He has held additional leadership roles at Merck, Biothera, AbbVie and Genentech/Roche. Bill has more than 25 years of experience in oncology, having begun his career as a practicing hematologist/oncologist with expertise in bone marrow transplants before moving into the biopharmaceutical industry. At the Medical College of Wisconsin, he was Founder and Medical Director of the Clinical Immunodiagnostic and Research Laboratory, Professor for Microbiology and Genetics and Director of the Bone Marrow Transplant Division for the Immunodeficiency Transplant Program. In addition, Bill currently serves on the Board of Directors for Day One Biopharmaceuticals and the Biopharma Advisory Board for Ginkgo Bioworks.

Bill received his MD and PhD in Immunology from Washington University School of Medicine’s Medical Scientist Training Program and completed his medical and post-doctoral training in the Divisions of Pediatrics and Medicine at Washington University School of Medicine.

Colin is a co-founder and Vice President, Synthetic Biology at Hexagon Bio, where he leads a cross-functional team of fungal geneticists, molecular biologists and engineers to discover therapeutically-relevant secondary metabolites. Previously, he led synthetic biology efforts for natural product discovery at the Stanford Genome Technology Center. Colin’s research interests lie in the discovery of new medicines using the tools of synthetic and molecular biology.

Colin holds a B.Sc. in Chemistry from McGill University, a Ph.D. in Chemistry from Stanford University, and completed postdoctoral training at the Stanford University School of Medicine.

Victor is Senior Vice President, Drug Discovery at Hexagon Bio. He obtained a B.S. degree in Chemistry from the University of Utah in 1997 and a Ph.D. degree in Organic Chemistry from Harvard University in 2003. He joined the Medicinal Chemistry department at Amgen in 2003 and contributed to numerous small molecule drug discovery programs including Tie-2 kinase, Aurora kinase (AMG 900), S1P1 (AMG 369), PI3K (AMG 511), Pim kinase, and RORT. He led the KRASG12C research team from project inception to the identification and characterization of AMG 510, which went on to become Amgen’s first in class KRASG12C inhibitor LUMAKRAS™ (sotorasib), approved in the United States in 2021 for the treatment of KRASG12C-positive non-small cell lung cancer. In 2020 he joined Oncovalent Therapeutics as Vice President, Chemistry, where he directed drug discovery efforts and platform technology focused on identifying and advancing covalent inhibitors for oncology indications.

Ana Radeljevic is a corporate development leader with 20+ years of experience building and growing multiple biotech and pharma companies. She has led the closing of more than $28 billion in M&A and licensing collaborations, and equity financing, including multiple IPOs. Ms. Radeljevic served as CBO of Tidal Therapeutics, where she played a pivotal role in the company’s sale to Sanofi for up to $460 million. Previously, she was a Vice President and Head of Business Development and Operations at Torque Therapeutics, where she was instrumental in closing a $72 million series B financing, leading the company’s merger with Cogen Therapeutics to form Repertoire Immune Medicines, and closing a $189 million crossover financing.

Earlier in her career, she served as a Vice President of Corporate Finance at PerkinElmer where she led the closing of several key acquisitions. Prior to that, she was the Head of Global Business Development and Strategic Planning for the Biosurgery business unit of Sanofi and Corporate Finance at Genzyme. She started her career at Deloitte in the Audit and subsequently M&A practice. She also serves as a board member and audit committee chair of Merrimack Pharmaceuticals (NASDAQ: MACK).

Ms. Radeljevic holds an MBA from the Whitman School of Management at Syracuse University and a BS in Business Administration from Old Dominion University. She is also a CFA charter holder and a CPA.

Andy is Vice President, Engineering at Hexagon Bio. Previously he was the Director of Engineering at Palantir Technologies, where he built out the engineering team and oversaw the development of Palantir Metropolis, a quantitative analytics platform. Andy also serves as an advisor to technology startups building their software engineering teams.

Andy studied computer science and mathematics at Stanford University.

Natacha is Vice President, Biology at Hexagon Bio. Natacha brings 15 years of R&D experience on platform technologies across multiple therapeutic areas including oncology, neurological, and inflammatory disorders. Prior to joining Hexagon, Natacha oversaw discovery and IND-stage programs for biologics and small molecules at Ashvattha, Catalyst Biosciences, and Omniox where she contributed to the expansion of companies’ preclinical portfolio and advancement of candidates from target identification to IND. Natacha holds a PhD in Molecular Biology from Paris-Sud University and was a postdoctoral fellow at the Gladstone Institute of Neurological Disease, University of California San Fransisco.

Brian Naughton is a co-founder of Hexagon Bio, together with Maureen Hillenmeyer, Colin Harvey and Yi Tang. He was previously Chief Technology Officer at Hexagon Bio and VP and founding scientist at 23andMe, where he worked on algorithm development for large-scale human genetics data. Brian’s research interests are in the genetics of disease and the analysis of biological data. Brian has a Ph.D. in Biomedical Informatics from Stanford University, and a B.A. in Human Genetics from Trinity College, Dublin.

Yi Tang is a co-founder of Hexagon Bio, together with Maureen Hillenmeyer, Brian Naughton and Colin Harvey. He is a world expert on fungal enzymes and natural products, and is currently the Chancellor Professor at the Department of Chemical and Biomolecular Engineering at the University of California, Los Angeles.